TORRENT PHARMACEUTICALS
|
TORRENT PHARMACEUTICALS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 63.92 | 56.47 | 48.94 | 36.79 | 45.92 |
| CEPS(Rs) | 96.23 | 79.96 | 72.82 | 57.67 | 42.52 |
| DPS(Rs) | 38.00 | 32.00 | 28.00 | 22.00 | 48.00 |
| Book NAV/Share(Rs) | 247.84 | 224.27 | 202.57 | 183.13 | 351.75 |
| Tax Rate(%) | 25.56 | 28.49 | 29.58 | 32.59 | 36.60 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 22.22 | 21.98 | 20.13 | 17.30 | 15.98 |
| EBIT Margin(%) | 16.55 | 17.36 | 16.20 | 13.36 | 9.74 |
| Pre Tax Margin(%) | 14.59 | 15.86 | 14.08 | 11.32 | 8.06 |
| PAT Margin (%) | 10.86 | 11.34 | 9.92 | 7.63 | 5.11 |
| Cash Profit Margin (%) | 16.55 | 16.06 | 14.75 | 11.96 | 9.46 |
| Performance Ratios | |||||
| ROA(%) | 7.37 | 13.23 | 11.43 | 9.20 | 5.92 |
| ROE(%) | 26.76 | 26.46 | 25.38 | 20.50 | 13.18 |
| ROCE(%) | 19.27 | 27.32 | 24.28 | 20.32 | 14.35 |
| Asset Turnover(x) | 0.68 | 1.17 | 1.15 | 1.21 | 1.16 |
| Sales/Fixed Asset(x) | 0.72 | 1.22 | 1.27 | 1.39 | 1.43 |
| Working Capital/Sales(x) | 18.77 | 18.62 | 89.70 | -122.18 | 20.28 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 1.38 | 0.82 | 0.79 | 0.72 | 0.70 |
| Receivable days | 45.41 | 40.18 | 41.38 | 39.99 | 37.86 |
| Inventory Days | 52.67 | 52.20 | 49.26 | 52.47 | 61.71 |
| Payable days | 244.06 | 279.17 | 279.66 | 243.50 | 306.08 |
| Valuation Parameters | |||||
| PER(x) | 66.03 | 57.28 | 53.15 | 41.79 | 30.45 |
| PCE(x) | 43.86 | 40.45 | 35.72 | 26.66 | 32.88 |
| Price/Book(x) | 17.03 | 14.42 | 12.84 | 8.40 | 7.95 |
| Yield(%) | 0.90 | 0.99 | 1.08 | 1.43 | 1.72 |
| EV/Net Sales(x) | 11.19 | 9.72 | 8.50 | 5.90 | 5.99 |
| EV/Core EBITDA(x) | 35.05 | 29.89 | 26.60 | 19.66 | 19.38 |
| EV/EBIT(x) | 48.04 | 38.26 | 33.68 | 26.03 | 34.40 |
| EV/CE(x) | 6.75 | 10.54 | 8.44 | 4.94 | 4.04 |
| M Cap / Sales | 10.22 | 9.51 | 8.21 | 5.41 | 5.56 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 21.39 | 7.35 | 11.51 | 13.07 | 6.29 |
| Core EBITDA Growth(%) | 19.25 | 9.30 | 18.65 | 9.87 | 3.58 |
| EBIT Growth(%) | 11.35 | 8.11 | 24.08 | 47.24 | -21.19 |
| PAT Growth(%) | 11.87 | 15.39 | 33.02 | 60.22 | -37.92 |
| EPS Growth(%) | 13.19 | 15.39 | 33.02 | -19.88 | -37.92 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 1.76 | 0.40 | 0.57 | 0.85 | 0.68 |
| Current Ratio(x) | 1.13 | 1.19 | 1.03 | 0.98 | 1.17 |
| Quick Ratio(x) | 0.75 | 0.66 | 0.62 | 0.57 | 0.62 |
| Interest Cover(x) | 8.46 | 11.59 | 7.65 | 6.54 | 5.81 |
| Total Debt/Mcap(x) | 0.10 | 0.03 | 0.04 | 0.10 | 0.08 |
Compare Financial Ratios of peers of TORRENT PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| TORRENT PHARMACEUTICALS | ₹149,528.8 Cr | 1.6% | 1.4% | 36.7% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹427,933.0 Cr | -0.7% | -3.6% | 6% | Stock Analytics | |
| DIVIS LABORATORIES | ₹175,833.0 Cr | 1.1% | -1.2% | -0.3% | Stock Analytics | |
| CIPLA | ₹113,155.0 Cr | 0.7% | 2.6% | -4.6% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹106,652.0 Cr | -0.9% | -2.5% | 1.2% | Stock Analytics | |
| MANKIND PHARMA | ₹96,492.8 Cr | 0.7% | -1.1% | -4.8% | Stock Analytics | |
TORRENT PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| TORRENT PHARMACEUTICALS | 1.6% |
1.4% |
36.7% |
| SENSEX | -0.7% |
-3.6% |
-9.1% |
You may also like the below Video Courses
